In our analysis, in the subgroup of new users of GLP-1RA and SGLT-2i treated with insulin in the previous 12 months, likely at a more advanced stage of diabetes, both cohorts displayed a similar risk of CV events occurrence. Here, INS is linked to diabetes mellitus.